Compare Stocks Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities. Stocks to Compare Sections All Sections Selected Performance Chart Price & Volume MarketRank Analyst Ratings Sales & Book Value Profitability & Earnings Dividends Debt Ownership Miscellaneous Headlines About Compare NASDAQ:BNRNASDAQ:OPGNNASDAQ:PIIINASDAQ:XGN On This Page Performance ChartPrice & VolumeMarketRank™Analyst RatingsSales & Book ValueProfitability & EarningsDividendsDebtOwnershipMiscellaneousHeadlinesAbout Comparison Ideas Stock Ideas Comparative Price Performance Over Time1 day7 days30 days90 days365 daysCompare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeBNRBurning Rock Biotech$4.34-3.6%$6.07$2.62▼$8.99$44.46M0.5514,367 shs1,445 shsOPGNOpGen$4.12+3.8%$1.56$0.53▼$8.40$34.43M0.347,397 shs40,063 shsPIIIP3 Health Partners$0.18+11.8%$0.19$0.15▼$0.89$65.84M0.94977,917 shs682,053 shsXGNExagen$3.93+9.5%$3.89$1.30▼$6.22$70.34M1.483,525 shs424,898 shs(Almost) Everything You Need To Know About The EV MarketLooking to profit from the electric vehicle mega-trend? Enter your email address and we'll send you our list of which EV stocks show the most long-term potential.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceBNRBurning Rock Biotech-3.89%-23.32%-30.33%-35.64%-40.34%OPGNOpGen0.00%+47.04%+344.82%+567.23%-42.88%PIIIP3 Health Partners-4.87%-11.96%-13.17%-27.03%-84.07%XGNExagen-6.51%-11.36%+3.76%-12.44%+125.79%Remove AdsCompare MarketRank™CompanyOverall ScoreAnalyst's OpinionShort Interest ScoreDividend StrengthESG ScoreNews and Social Media SentimentCompany OwnershipEarnings & ValuationBNRBurning Rock Biotech0.7429 of 5 stars0.03.00.00.01.81.70.6OPGNOpGenN/AN/AN/AN/AN/AN/AN/AN/APIIIP3 Health Partners1.8866 of 5 stars3.03.00.00.01.00.81.3XGNExagen4.6828 of 5 stars3.55.00.04.53.13.30.6Compare Analyst ForecastsCompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current PriceBNRBurning Rock Biotech 0.00N/AN/AN/AOPGNOpGen 0.00N/AN/AN/APIIIP3 Health Partners 2.00Hold$0.2536.24% UpsideXGNExagen 3.00Buy$7.5090.84% UpsideCurrent Analyst Ratings BreakdownLatest OPGN, XGN, PIII, and BNR Analyst RatingsDateCompanyBrokerageActionRatingPrice TargetDetails3/12/2025XGNExagenWilliam BlairSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingOutperform1/13/2025XGNExagenCantor FitzgeraldSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingOverweight ➝ Overweight$8.00 ➝ $8.001/3/2025XGNExagenCanaccord Genuity GroupSubscribe to MarketBeat All Access for the recommendation accuracy ratingBoost Price TargetBuy ➝ Buy$5.00 ➝ $7.00(Data available from 4/1/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)Compare Sales & Book ValueCompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/BookBNRBurning Rock Biotech$515.82M0.09N/AN/A$10.56 per share0.41OPGNOpGen$2.67M12.88N/AN/A($11.55) per share-0.36PIIIP3 Health Partners$1.48B0.04$0.08 per share2.32$0.45 per share0.41XGNExagen$55.64M1.26N/AN/A$1.33 per share2.95Compare Profitability & EarningsCompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings DateBNRBurning Rock Biotech-$92.07M-$1.88N/A∞N/A-83.50%-60.68%-42.30%N/AOPGNOpGen-$32.67MN/A0.00∞N/A-1,140.36%N/A-287.58%6/2/2025 (Estimated)PIIIP3 Health Partners-$57.77M-$0.98N/AN/AN/A-6.95%-71.31%-11.93%5/6/2025 (Estimated)XGNExagen-$23.69M-$0.83N/AN/AN/A-30.36%-92.58%-33.74%5/12/2025 (Estimated)Latest OPGN, XGN, PIII, and BNR EarningsDateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails3/27/2025Q4 2024PIIIP3 Health Partners-$0.17-$0.32-$0.15-$0.36$378.88 million$370.69 million3/25/2025Q4 2024BNRBurning Rock Biotech-$1.3970-$1.08+$0.3170-$1.08N/A$17.27 millionCompare DividendsCompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive GrowthBNRBurning Rock BiotechN/AN/AN/AN/AN/AOPGNOpGenN/AN/AN/AN/AN/APIIIP3 Health PartnersN/AN/AN/AN/AN/AXGNExagenN/AN/AN/AN/AN/ACompare DebtCompanyDebt-to-Equity RatioCurrent RatioQuick RatioBNRBurning Rock BiotechN/A3.042.78OPGNOpGenN/A5.455.45PIIIP3 Health Partners1.110.530.53XGNExagen1.544.054.05Compare OwnershipInstitutional OwnershipCompanyInstitutional OwnershipBNRBurning Rock Biotech30.03%OPGNOpGen2.68%PIIIP3 Health Partners7.75%XGNExagen75.25%Insider OwnershipCompanyInsider OwnershipBNRBurning Rock Biotech30.30%OPGNOpGen43.80%PIIIP3 Health Partners15.76%XGNExagen26.10%Compare Miscellaneous StatsCompanyEmployeesShares OutstandingFree FloatOptionableBNRBurning Rock Biotech1,39010.24 million7.14 millionNot OptionableOPGNOpGen1008.36 million4.70 millionNot OptionablePIIIP3 Health Partners500358.82 million294.74 millionNot OptionableXGNExagen22017.90 million13.03 millionOptionableOPGN, XGN, PIII, and BNR HeadlinesRecent News About These CompaniesShort Interest in Exagen Inc. (NASDAQ:XGN) Drops By 23.5%March 31 at 1:12 AM | marketbeat.comExagen Inc. (NASDAQ:XGN) Sees Significant Decline in Short InterestMarch 16, 2025 | marketbeat.comCantor Fitzgerald Reduces Earnings Estimates for ExagenMarch 15, 2025 | marketbeat.comWilliam Blair Forecasts Exagen's Q1 Earnings (NASDAQ:XGN)March 15, 2025 | marketbeat.comExagen Inc. (NASDAQ:XGN) Just Reported Annual Earnings: Have Analysts Changed Their Mind On The Stock?March 14, 2025 | finance.yahoo.comWilliam Blair Predicts Exagen's FY2026 Earnings (NASDAQ:XGN)March 14, 2025 | marketbeat.comWilliam Blair Reiterates Outperform Rating for Exagen (NASDAQ:XGN)March 13, 2025 | marketbeat.comExagen Full Year 2024 Earnings: EPS Beats ExpectationsMarch 12, 2025 | uk.finance.yahoo.comExagen Inc. (NASDAQ:XGN) Q4 2024 Earnings Call TranscriptMarch 12, 2025 | msn.comExagen (XGN) Gets a Buy from Canaccord GenuityMarch 12, 2025 | markets.businessinsider.comExagen Inc. Reports Record Revenue and Positive OutlookMarch 12, 2025 | tipranks.comExagen (NASDAQ:XGN) Releases Quarterly Earnings Results, Beats Estimates By $0.07 EPSMarch 12, 2025 | marketbeat.comCantor Fitzgerald Forecasts Increased Earnings for ExagenMarch 12, 2025 | marketbeat.comExagen reports Q4 EPS (20c), consensus (24c)March 12, 2025 | markets.businessinsider.comExagen Inc. Reports Record 2024 Financial ResultsMarch 12, 2025 | tipranks.comExagen Inc. (XGN) Q4 2024 Earnings Call TranscriptMarch 11, 2025 | seekingalpha.comExagen Inc. Reports Strong Fourth Quarter and Full-Year 2024 Results and Business HighlightsMarch 11, 2025 | globenewswire.comExagen Inc. (NASDAQ:XGN) Short Interest UpdateMarch 6, 2025 | marketbeat.comExagen (XGN) to Release Quarterly Earnings on TuesdayMarch 4, 2025 | marketbeat.comInvestors in Exagen (NASDAQ:XGN) have unfortunately lost 84% over the last five yearsMarch 2, 2025 | finance.yahoo.comExagen Inc. to Announce Fourth Quarter and Full-Year 2024 Financial Results on March 11, 2025February 25, 2025 | globenewswire.comNew MarketBeat Followers Over TimeMedia Sentiment Over TimeOPGN, XGN, PIII, and BNR Company DescriptionsBurning Rock Biotech NASDAQ:BNR$4.45 -0.05 (-1.11%) As of 04:00 PM Eastern This is a fair market value price provided by Polygon.io. Learn more.Burning Rock Biotech Limited primarily develops and commercializes cancer therapy selection tests in the People's Republic of China. It operates in three segments: Central Laboratory Business, In-Hospital Business, and Pharma Research and Development Services. The company primarily offers next-generation sequencing-based tissue and liquid biopsy cancer therapy selection and prognosis prediction tests for various range of cancer types, including lung cancer, gastrointestinal cancer, prostate cancer, breast cancer, lymphomas, thyroid cancer, colorectal cancer, ovarian cancer, pancreatic cancer, and bladder cancer using tissue and liquid biopsy samples. Its principal products include OncoCompass IO, a corresponding test for liquid biopsy samples; OncoScreen IO, a pan-cancer test for tissue samples; and OncoCompass Target, a ctDNA liquid biopsy-based test for NSCLC. In addition, the company provides ColonCore for assessing microsatellite loci related to MSI status and detecting mutations in genes associated with gastrointestinal cancers; and brPROPHET, a pre-operative ctDNA detection and post-operative MRD calling for relapsed patients. Further, it has development and commercialization agreement with Myriad Genetics, Inc. to in-license Myriad myChoice tumor testing in China; licensing agreement with Oncocyte Corporation to in-license DetermaRx, a risk stratification test for early stage lung cancer patients in China; and collaborations on clinical trials and research studies with AstraZeneca, Bayer, Johnson & Johnson, CStone, BeiGene, Abbisko Therapeutics, and IMPACT Therapeutics and Merck KGaA. Additionally, the company offers OncoMaster, an automatic NGS data analysis and report interpretation machine for in-hospital model. Burning Rock Biotech Limited was incorporated in 2014 and is headquartered in Guangzhou, China.OpGen NASDAQ:OPGN$4.12 +0.15 (+3.78%) As of 03:56 PM EasternOpGen, Inc., a precision medicine company, engages in developing and commercializing molecular microbiology solutions in the United States and internationally. Its product portfolio includes Acuitas AMR Gene Panel, an in vitro diagnostic (IVD) test for the detection and identification of various bacterial nucleic acids and genetic determinants of antimicrobial resistance (AMR) from bacterial colonies isolated from any specimen, as well as Curetis CE-IVD-marked polymerase chain reaction-based SARS-CoV-2 test kits. The company's products also comprise ARES Technology Platform, including ARES reference database on antimicrobial resistance using next generation sequencing technology and artificial intelligence powered bioinformatics solutions for antibiotic response prediction; and Unyvero Platform, an automated sample-to-answer molecular diagnostics platform that integrates automated sample preparation, analysis, and identification of disease relevant pathogens and antibiotic resistance markers. It also utilizes molecular diagnostics and informatics to help combat infectious diseases. The company helps clinicians with information about life threatening infections to enhance patient outcomes, and to decrease the spread of infections caused by multidrug-resistant microorganisms. OpGen, Inc. has a collaboration with the New York State Department of Health and ILÚM Health Solutions, LLC to develop a research program to detect, track, and manage antimicrobial-resistant infections at healthcare institutions. The company was incorporated in 2001 and is headquartered in Rockville, Maryland.P3 Health Partners NASDAQ:PIII$0.18 +0.02 (+11.82%) Closing price 04:00 PM EasternExtended Trading$0.18 0.00 (-0.27%) As of 07:50 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.P3 Health Partners Inc., a patient-centered and physician-led population health management company, provides superior care services in the United States. It operates clinics and wellness centers. P3 Health Partners Inc. was founded in 2020 and is based in Henderson, Nevada.Exagen NASDAQ:XGN$3.93 +0.34 (+9.47%) Closing price 04:00 PM EasternExtended Trading$3.78 -0.15 (-3.82%) As of 07:46 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Exagen Inc. develops and commercializes various testing products under the AVISE brand in the United States. The company enables healthcare providers to care for patients through the diagnosis, prognosis, and monitoring of autoimmune and autoimmune-related diseases, including systemic lupus erythematosus (SLE) and rheumatoid arthritis (RA). Its lead testing product is AVISE CTD that enables differential diagnosis for patients presenting with symptoms indicative of various connective tissue diseases (CTDs) and other related diseases with overlapping symptoms. The company offers AVISE Lupus that measures activation of the complement system by quantifying the level of B-cell C4d and erythrocyte bound C4d in the patient's blood; and AVISE APS, which consists of a panel of autoantibody tests that aids in the diagnosis and management of APS. In addition, it provides AVISE Vasculitis AAV, which utilizes a testing panel of individual analytes to provide physicians with results in the assessment and monitoring of anti-neutrophil cytoplasmic antibody associated vasculitis; AVISE SLE Prognostic, a panel of autoantibodies for assessing the potential for complications affecting the kidney, brain, and cardiovascular system; and AVISE Anti-CarP test, which identifies RA patients with severe disease. Further, the company offers AVISE SLE Monitor, a biomarker blood test; AVISE MTX, a patented and validated blood test; and AVISE HCQ, a blood test to monitor levels of hydroxychloroquine. It has a research collaboration and license agreement with Allegheny Health Network (AHN) Research Institute to develop novel patented biomarkers. The company was formerly known as Exagen Diagnostics, Inc. and changed its name to Exagen Inc. in January 2019. Exagen Inc. was incorporated in 2002 and is headquartered in Vista, California. More Stock Comparisions from MarketBeat Stock Comparison Ideas (A-K)5GAgricultureAirlineAmerica FirstApparelArtificial IntelligenceAutomotiveBankBiotechBitcoinBlockchainBlue ChipCanadianCannabisCasinoChatGPTChineseCloud StorageCryptocurrencyCybersecurityDefenseDividendDow 30EcommerceElectric VehiclesEnergyEntertainmenteSportsEV ChargingFertilizerGoldGroceryGrowthHealthcareHigh DividendHotelStock Comparison Ideas (L-Z)Large CapLeisureLithiumMagnificent SevenMega CapMemeMetaverseMid CapMiningMusic IndustryNanotechnologyNFTNuclear EnergyOilPharmaceuticalQuantum ComputingRenewable EnergyRestaurantRetailSemiconductorSocial MediaSolarSpaceTechnologyTelecomToyUtilityVideo GameVirtual RealityWallStreetBets More Stock Ideas from MarketBeat Stock Lists 5G Stocks Biotech Stocks Blue Chip Stocks DOW 30 Stocks FAANG Stocks Gold Stocks Large Cap Stocks Lumber Stocks Marijuana Stocks Micro Cap Stocks Oil Stocks REITs Small Cap Stocks SPACs Travel Stocks Trillion Dollar Stocks Water Stocks Warren Buffett Stocks Low Priced Stocks Penny Stock List Popular Penny Stocks Top Stocks Today Stocks on Sale Stocks Under $0.05 Stocks Under $0.10 Stocks Under $0.25 Stocks Under $0.50 Stocks Under $1 Stocks Under $2 Stocks Under $3 Stocks Under $5 Stocks Under $10 Stocks Under $20 Stocks Under $30 Stocks Under $50 Stocks By Exchange NASDAQ Stocks NYSE Stocks NYSEAMERICAN Stocks NYSEARCA Stocks NYSEMKT Stocks OTCMKTS Stocks TSX Stocks TSXV Stocks LSE Stocks BATS Stocks Latest Stock Ideas D-Wave: Multiple Use Cases Emerge Following Quantum Supremacy Amazon Falls Back to a Key Support Line: Here's How to Play It Berkshire Hathaway Gains Defy Stock Market Slump Tech Sell-Off Makes Microsoft Stock Look Like a Steal Palantir Stock Builds Momentum on New Partnership Amprius Market Gets Amped Up on Growth Outlook 3 Buyable Stocks With Solid Bottoms Ready to Rebound Game-Changing News for Advanced Micro Devices Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
